Literature DB >> 17030735

DDD mice, a novel acute mouse model of Parkinson's disease.

Tatyana D Sotnikova1, Marc G Caron, Raul R Gainetdinov.   

Abstract

We describe the development of a novel animal model of acute severe dopamine (DA) deficiency by using genetically altered mice lacking the DA transporter (DAT-KO mice). In the absence of a DAT-mediated recycling mechanism in these mice, striatal DA concentrations become entirely dependent on its de novo synthesis, and acute pharmacologic inhibition of tyrosine hydroxylase induces transient (up to 16 hours) elimination of brain DA. Dopamine-deficient DAT-KO mice (DDD mice) demonstrate a striking behavioral phenotype manifested as severe akinesia, rigidity, tremor, and ptosis. We propose that DDD mice represent a novel acute model of severe DA deficiency that might be used to identify compounds with potential therapeutic use for the treatment of Parkinson's disease (PD). This model is particularly promising as a tool for evaluating the efficacy of compounds that may induce movement independently of DA. The advantages and limitations of DDD mice in comparison to other rodent PD models are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17030735     DOI: 10.1212/wnl.67.7_suppl_2.s12

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  L-Dopa activates histaminergic neurons.

Authors:  Yevgenij Yanovsky; Sha Li; Boris P Klyuch; Qiaoling Yao; Patrizio Blandina; M Beatrice Passani; Jian-Sheng Lin; Helmut L Haas; Olga A Sergeeva
Journal:  J Physiol       Date:  2011-01-17       Impact factor: 5.182

2.  Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.

Authors:  Nikhil M Urs; Simone Bido; Sean M Peterson; Tanya L Daigle; Caroline E Bass; Raul R Gainetdinov; Erwan Bezard; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

3.  Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans.

Authors:  C Dong; M-L Wong; J Licinio
Journal:  Mol Psychiatry       Date:  2009-10-20       Impact factor: 15.992

4.  The dopamine metabolite 3-methoxytyramine is a neuromodulator.

Authors:  Tatyana D Sotnikova; Jean-Martin Beaulieu; Stefano Espinoza; Bernard Masri; Xiaodong Zhang; Ali Salahpour; Larry S Barak; Marc G Caron; Raul R Gainetdinov
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

5.  A new knock-in mouse model of l-DOPA-responsive dystonia.

Authors:  Samuel J Rose; Xin Y Yu; Ann K Heinzer; Porter Harrast; Xueliang Fan; Robert S Raike; Valerie B Thompson; Jean-Francois Pare; David Weinshenker; Yoland Smith; Hyder A Jinnah; Ellen J Hess
Journal:  Brain       Date:  2015-07-27       Impact factor: 13.501

6.  Biphasic mechanisms of amphetamine action at the dopamine terminal.

Authors:  Cody A Siciliano; Erin S Calipari; Mark J Ferris; Sara R Jones
Journal:  J Neurosci       Date:  2014-04-16       Impact factor: 6.167

Review 7.  Dopamine transporter mutant mice in experimental neuropharmacology.

Authors:  Raul R Gainetdinov
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-05       Impact factor: 3.000

8.  Novel translational rat models of dopamine transporter deficiency.

Authors:  Damiana Leo; Ilya Sukhanov; Raul R Gainetdinov
Journal:  Neural Regen Res       Date:  2018-12       Impact factor: 5.135

9.  Enhanced Dopamine Transmission and Hyperactivity in the Dopamine Transporter Heterozygous Mice Lacking the D3 Dopamine Receptor.

Authors:  Tatyana D Sotnikova; Evgeniya V Efimova; Raul R Gainetdinov
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.